Research
Quadruple Agonist Reduced Weight Without Major Muscle Loss in Mid-Stage Trial
The Brief
- A randomized phase II trial of an investigational oral quadruple receptor agonist was presented at ObesityWeek in National Harbor, Md.
- The trial reported substantial weight loss with preservation of lean mass.
- By week 13, the two highest tested doses had produced the reported weight loss, according to the source excerpt, which is truncated.
Why it matters
If later trials confirm that weight loss can occur without major muscle loss, it could change how clinicians weigh the benefits and risks of obesity drugs. These are mid-stage results for an investigational drug, so they are early evidence.
Who’s affected
- clinicians and researchers in obesity medicine
- people with obesity who are considering weight-loss treatments
(MedPage Today) -- NATIONAL HARBOR, Md. -- An investigational oral quadruple receptor agonist led to substantial weight loss with preservation of lean mass, a randomized phase II trial presented here showed. By week 13, the two highest tested...